The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1715
November 4, 2024
View Complete Issue         Table of Contents 2019 
Issue 1715
Subscribers: Log in to read full issue.  Not a subscriber?  Subscribe or purchase issue.
Xanomeline/Trospium (Cobenfy) for Schizophrenia
November 11, 2024 (Issue: 1715)
The FDA has approved Cobenfy (BMS), an oral fixed-dose combination of the muscarinic agonist xanomeline and the peripheral muscarinic antagonist trospium chloride, for treatment of schizophrenia in adults. It is the first antipsychotic drug to be...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this issue?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this issue:
Title: Issue 1715
 


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.